Leerink Partnrs Forecasts Higher Earnings for Immunocore

Immunocore Holdings plc (NASDAQ:IMCR - Free Report) - Analysts at Leerink Partnrs raised their FY2024 EPS estimates for Immunocore in a research report issued to clients and investors on Wednesday, November 6th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings of ($1.48) per share for the year, up from their previous forecast of ($2.20). The consensus estimate for Immunocore's current full-year earnings is ($1.71) per share. Leerink Partnrs also issued estimates for Immunocore's Q4 2024 earnings at ($0.93) EPS and FY2025 earnings at ($2.59) EPS.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.50. Immunocore had a negative return on equity of 14.68% and a negative net margin of 19.16%. The company had revenue of $80.25 million for the quarter, compared to analyst estimates of $78.94 million. During the same quarter last year, the company earned ($0.59) earnings per share. The firm's quarterly revenue was up 23.7% compared to the same quarter last year.

Several other equities analysts have also commented on IMCR. Oppenheimer reissued an "outperform" rating and issued a $89.00 target price (up from $87.00) on shares of Immunocore in a report on Friday, August 9th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Immunocore in a report on Monday, September 9th. HC Wainwright reissued a "buy" rating and set a $100.00 price target on shares of Immunocore in a report on Thursday, October 24th. Barclays reduced their price objective on Immunocore from $92.00 to $66.00 and set an "overweight" rating on the stock in a research note on Friday, August 9th. Finally, Needham & Company LLC lowered their target price on Immunocore from $78.00 to $71.00 and set a "buy" rating for the company in a research note on Thursday. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $73.73.

Immunocore Stock Performance

Shares of NASDAQ:IMCR traded up $0.38 on Friday, reaching $34.69. 199,461 shares of the company's stock were exchanged, compared to its average volume of 525,921. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of -31.68 and a beta of 0.72. Immunocore has a twelve month low of $29.72 and a twelve month high of $76.98. The company has a current ratio of 5.17, a quick ratio of 5.15 and a debt-to-equity ratio of 1.31. The company has a fifty day moving average of $32.66 and a 200-day moving average of $39.66.

Institutional Investors Weigh In On Immunocore

Institutional investors have recently made changes to their positions in the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in shares of Immunocore by 86.3% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 342,000 shares of the company's stock worth $22,230,000 after acquiring an additional 158,455 shares during the period. Orion Portfolio Solutions LLC increased its position in shares of Immunocore by 33.7% during the first quarter. Orion Portfolio Solutions LLC now owns 23,127 shares of the company's stock worth $1,503,000 after buying an additional 5,826 shares during the period. Nan Fung Group Holdings Ltd acquired a new position in Immunocore in the first quarter valued at $439,000. Janus Henderson Group PLC grew its holdings in Immunocore by 45.8% during the 1st quarter. Janus Henderson Group PLC now owns 257,080 shares of the company's stock worth $16,711,000 after acquiring an additional 80,748 shares during the period. Finally, Tidal Investments LLC acquired a new position in shares of Immunocore in the 1st quarter valued at about $423,000. Institutional investors own 84.50% of the company's stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.